Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Videos [1649]

Paediatric ALL with brain metastases

Dr Christina Halsey - University of Glasgow, Glasgow, UK

Paediatric ALL with brain metastases ( Dr Christina Halsey - University of Glasgow, Glasgow, UK )

miRNA screening for germ cell tumours

Dr Matthew Murray - University of Cambridge, Cambridge, UK

miRNA screening for germ cell tumours ( Dr Matthew Murray - University of Cambridge, Cambridge, UK )

ALK mutations in paediatric tumours

Dr Suzanne Turner - Cambridge University, Cambridge, UK

ALK mutations in paediatric tumours ( Dr Suzanne Turner - Cambridge University, Cambridge, UK )

NCI’s precision medicine initiatives

Dr Shakun Malik - National Cancer Institute, USA

NCI’s precision medicine initiatives ( Dr Shakun Malik - National Cancer Institute, USA )

Omics, early detection and novel therapies: Q & A

Dr Murrell and Dr Pardo

Omics, early detection and novel therapies: Q & A ( Dr Murrell and Dr Pardo )

Omics, early detection and novel therapies: Metabolomics

Dr Olivier Pardo - Imperial College London, London, UK

Omics, early detection and novel therapies: Metabolomics ( Dr Olivier Pardo - Imperial College London, London, UK )

Omics, early detection and novel therapies: Epigenetic studies

Dr Adele Murrell - University of Bath, Bath, UK

Omics, early detection and novel therapies: Epigenetic studies ( Dr Adele Murrell - University of Bath, Bath, UK )

We should use PDL1 and other biomarkers for selecting patients for immune...

Dr Mary O’Brien - The Royal Marsden NHS Foundation Trust, London, UK

We should use PDL1 and other biomarkers for selecting patients for immune checkpoint therapies ( Dr Mary O’Brien - The Royal Marsden NHS Foundation Trust, London, UK )

We should not use PDL1 and other biomarkers for selecting patients for immune...

Prof Gordon McVie - King's College London, London, UK

We should not use PDL1 and other biomarkers for selecting patients for immune checkpoint therapies ( Prof Gordon McVie - King's College London, London, UK )

Can we reduce exposure to risk factors associated with childhood leukaemia and...

Dr Mark Miller - UCSF, San Francisco, USA

Can we reduce exposure to risk factors associated with childhood leukaemia and other cancers? ( Dr Mark Miller - UCSF, San Francisco, USA )

Design and value of immunohistochemical assays

Dr Stephen Hewitt - National Institutes of Health, Bethesda, USA

Design and value of immunohistochemical assays ( Dr Stephen Hewitt - National Institutes of Health, Bethesda, USA )

Oncolytic virotherapy in the treatment of melanoma

Dr Robert Andtbacka - Huntsman Cancer Institute, Salt Lake City, USA

Oncolytic virotherapy in the treatment of melanoma ( Dr Robert Andtbacka - Huntsman Cancer Institute, Salt Lake City, USA )

More from ecancer